Wells Fargo’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-199,400
| Closed | -$4.33M | – | 6649 |
|
|
2017
Q2 | $4.33M | Buy |
199,400
+30,793
| +18% | +$559K | ﹤0.01% | 2567 |
|
|
2017
Q1 | $2.37M | Buy |
168,607
+29,338
| +21% | +$480K | ﹤0.01% | 3055 |
|
|
2016
Q4 | $2.61M | Buy |
139,269
+27,270
| +24% | +$464K | ﹤0.01% | 2941 |
|
|
2016
Q3 | $1.85M | Buy |
111,999
+39,975
| +56% | +$592K | ﹤0.01% | 3031 |
|
|
2016
Q2 | $968K | Buy |
72,024
+18,794
| +35% | +$274K | ﹤0.01% | 3501 |
|
|
2016
Q1 | $814K | Buy |
53,230
+4,941
| +10% | +$77.4K | ﹤0.01% | 3536 |
|
|
2015
Q4 | $958K | Buy |
48,289
+32,485
| +206% | +$617K | ﹤0.01% | 3503 |
|
|
2015
Q3 | $275K | Sell |
15,804
-6,713
| -30% | -$137K | ﹤0.01% | 4290 |
|
|
2015
Q2 | $455K | Buy |
22,517
+5,013
| +29% | +$96.7K | ﹤0.01% | 4155 |
|
|
2015
Q1 | $308K | Buy |
17,504
+16,412
| +1,503% | +$280K | ﹤0.01% | 4209 |
|
|
2014
Q4 | $18K | Sell |
1,092
-57,294
| -98% | -$1.05M | ﹤0.01% | 5423 |
|
|
2014
Q3 | $1.29M | Buy |
58,386
+56,518
| +3,026% | +$1.16M | ﹤0.01% | 3303 |
|
|
2014
Q2 | $38K | Buy |
1,868
+1,628
| +678% | +$27.6K | ﹤0.01% | 5082 |
|
|
2014
Q1 | $4K | Buy |
240
+184
| +329% | +$2.53K | ﹤0.01% | 5601 |
|
|
2013
Q4 | $1K | Sell |
56
-33,099
| -100% | -$400K | ﹤0.01% | 5663 |
|
|
2013
Q3 | $427K | Buy |
33,155
+31,671
| +2,134% | +$390K | ﹤0.01% | 3837 |
|
|
2013
Q2 | $18K | Buy |
+1,484
| New | +$16.1K | ﹤0.01% | 4913 |
|
Other funds holding AMRI
Wells Fargo's AMRI Position: Q3 2017 in Review
Wells Fargo sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 199,400 shares — an estimated $4.33M sold.
Wells Fargo first reported a position in AMRI in Q2 2013 and held it in 17 quarters. The position peaked at $4.33M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- Wells Fargo reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- Wells Fargo sold 199,400 Albany Molecular Research Inc shares in Q3 2017, an estimated $4.33M.
- Wells Fargo first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 17 quarters.
- Wells Fargo's Albany Molecular Research Inc position peaked at $4.33M in Q2 2017.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on Wells Fargo's 13F filing for Q3 2017, filed 9 Nov 2017.